Search company, investor...

GliaPharm

gliapharm.com

Founded Year

2016

Stage

Convertible Note | Alive

Total Raised

$2.27M

Last Raised

$100K | 7 mos ago

About GliaPharm

GliaPharm is a biotechnology company that develops treatments for neurological and psychiatric disorders. Its therapeutic approach is to target glial cells, the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. These pathologies, which all share similar glial and metabolic dysfunctions, include Alzheimer's disease, mild cognitive impairments, amyotrophic lateral sclerosis, and depression. The company was founded in 2016 and is based in Geneva, Switzerland.

Headquarters Location

Campus Biotech Ch. des Mines 9

Geneva, 1202,

Switzerland

Missing: GliaPharm's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: GliaPharm's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing GliaPharm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GliaPharm is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

GliaPharm Patents

GliaPharm has filed 6 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Rare diseases
  • Psychiatric diagnosis
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/20/2018

Neurological disorders, Rare diseases, Motor neurone disease, Motor neuron diseases, Syndromes

Application

Application Date

12/20/2018

Grant Date

Title

Related Topics

Neurological disorders, Rare diseases, Motor neurone disease, Motor neuron diseases, Syndromes

Status

Application

Latest GliaPharm News

GliaPharm and UCB enter drug discovery research collaboration

Oct 28, 2022

GliaPharm, focussed on innovative approaches to treat neurological and psychiatric disorders by targeting glial cells in the brain, has entered a strategic collaboration with global biopharmaceutical company UCB for the discovery of innovative therapeutic targets in epilepsy. This validates the general approach of GliaPharm as well as its proprietary technology platform.

GliaPharm Frequently Asked Questions (FAQ)

  • When was GliaPharm founded?

    GliaPharm was founded in 2016.

  • Where is GliaPharm's headquarters?

    GliaPharm's headquarters is located at Campus Biotech, Geneva.

  • What is GliaPharm's latest funding round?

    GliaPharm's latest funding round is Convertible Note.

  • How much did GliaPharm raise?

    GliaPharm raised a total of $2.27M.

  • Who are the investors of GliaPharm?

    Investors of GliaPharm include Fongit Seed Invest, Gliaven, Swiss Federal Institute of Technology Lausanne, Foundation for Technological Innovation and MassChallenge.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.